A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older
Completed · Phase 1, Phase 2 · NCT06744205
Conditions: Influenza, Healthy Volunteers
At a glance
- Research payments reported, 2025
- $10.5M
- U.S. investigators named
- 23
- Sites paid
- 13
- Planned or actual enrollment
- 1,162
About the trial
- Sponsor
- Sanofi Pasteur, a Sanofi Company
- Tested
- Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1 (biological), TIV mRNA-neuraminidase (NA) (biological), TIV mRNA-HA Vaccine 2 (biological), Quadrivalent Influenza Standard Dose Vaccine (biological), Quadrivalent Influenza Vaccine High Dose (biological)
- Dates
- Started 2025-01-06; completion 2026-05-22
- Results posted
- Not yet
The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular injection of different formulations of a hexavalent influenza messenger ribonucleic acid (mRNA) vaccine composed of differing dose levels of trivalent (TIV) mRNA hemagglutinin (HA) in combination with TIV mRNA-neuraminidase (NA) compared to an active control ((Fluzone standard-dose quadrivalent influenza vaccine (QIV-SD) or Fluzone high-dose quadrivalent influenza vaccine (QIV-HD) in adults 50 years of age and older.
From ClinicalTrials.gov, last updated 2026-06-09. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi Pasteur Inc. reported $10.5M in research payments for this study in 2025 (256 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Ramana K. Puppala, M.D. OB-GYN (Obstetrics & Gynecology) · Greenville, AL
- Faheem M. Shaikh, MD PHD Hospitalist · Birmingham, AL
- Harry E. Studdard II, MD Internal Medicine · Mobile, AL
- Cory Anderson, MD Family Medicine · Mesa, AZ
- Abid H. Chaudhry, M.D. Emergency Medicine · Homestead, FL
- Karen Figueredo Reyes, MD Family Medicine · Palmetto Bay, FL
- Eva-maria Heurich, D.O. Family Medicine · Orlando, FL
- Bruce G. Rankin, D. O. Family Medicine · Deland, FL
- Pedro P. Ylisastigui, M.D. Internal Medicine · Lehigh Acres, FL
- Manohar L. Jethani, MD Family Medicine · Berwyn, IL
- Martha S. Fanning, M.D. Emergency Medicine · Overland Park, KS
- Terry D. Klein, M.D. Family Medicine · Wichita, KS
- Stacy B. Slechta, DO Family Medicine · Newton, KS
- Mark S. Adams, M.D. Internal Medicine · London, KY
- Antonio C. Mendes, M.D Internal Medicine · Roslindale, MA
- Sanjay Rajagopalan, MD Cardiology · Baltimore, MD
- Kiran A. Saraiya, D.O. Nephrology (Kidney) · Warren, MI
- Bertrand P. Cole, DO Addiction Medicine · Somersworth, NH
- Adam S. Tanzer, MD Emergency Medicine · Laconia, NH
- Michael B. Jacobs, M.D., PH.D. Internal Medicine · Las Vegas, NV
- Shannon M. Conrad, D.O. Family Medicine · N Charleston, SC
- Jerry L. Punch, MD Family Medicine · Knoxville, TN
- James R. Clark, MD Internal Medicine · Charlottesville, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Alliance for Multispecialty Research,llc $3.6M
- Sandhill Research, Llc $1.4M
- Coastal Carolina Research Center,incorporation $1.0M
- Innovation Medical Research Center, Inc $942,947
- University Clinical Research Dela Llc $884,792
- Alliance for Multispecialty Research Llc $630,293
- Charlottesville Medical Research Center,llc $619,415
- Quest Research Institute Llc $471,755
- Achieve Clinical Research Llc Accel Research Sites $328,623
- Activmed Practices and Research Llc $230,536
- Boston Clinical Trials Llc $184,512
- The Children's Mercy Hospital, MO $110,000
- Achieve Clinical Research LLC $99,828
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.